{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:50:09Z","timestamp":1780357809470,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,4]]},"DOI":"10.7759\/cureus.48276","type":"journal-article","created":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T01:57:51Z","timestamp":1699149471000},"source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Ahmed","family":"Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elgebaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01207.x","article-title":"Iron overload and toxicity: the hidden risk of multiple blood transfusions","volume":"97","author":"Shander A","year":"2009","unstructured":"Shander A, Cappellini MD, Goodnough LT. Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox Sang. 2009, 97:185-97. 10.1111\/j.1423-0410.2009.01207.x","journal-title":"Vox Sang"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2450\/2012.0008-12","article-title":"An update on iron chelation therapy","volume":"10","author":"Poggiali E","year":"2012","unstructured":"Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. An update on iron chelation therapy. Blood Transfus. 2012, 10:411-22. 10.2450\/2012.0008-12","journal-title":"Blood Transfus"},{"key":"ref3","article-title":"Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients","volume":"21","author":"Lee P","year":"1993","unstructured":"Lee P, Mohammed N, Marshall L, Abeysinghe RD, Hider RC, Porter JB, Singh S. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab Dispos. 1993, 21:640-4.","journal-title":"Drug Metab Dispos"},{"key":"ref4","article-title":"","author":"Porter J","year":"2014","unstructured":"Porter J, Viprakasit V, Kattamis A. Iron Overload and Chelation. Thalassaemia International Federation, Nicosia; 2014. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK269373\/."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1006\/bcmd.2002.0510","article-title":"Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial","volume":"28","author":"Maggio A","year":"2002","unstructured":"Maggio A, D'Amico G, Morabito A, et al.. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002, 28:196-208. 10.1006\/bcmd.2002.0510","journal-title":"Blood Cells Mol Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2948","article-title":"Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis","volume":"107","author":"Pennell DJ","year":"2006","unstructured":"Pennell DJ, Berdoukas V, Karagiorga M, et al.. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006, 107:3738-44. 10.1182\/blood-2005-07-2948","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00071.x","article-title":"Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan","volume":"70","author":"Peng CT","year":"2003","unstructured":"Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH. Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol. 2003, 70:392-7. 10.1034\/j.1600-0609.2003.00071.x","journal-title":"Eur J Haematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia","volume":"107","author":"Cappellini MD","year":"2006","unstructured":"Cappellini MD, Cohen A, Piga A, et al.. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006, 107:3455-62. 10.1182\/blood-2005-08-3430","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01228.x","article-title":"Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study","volume":"82","author":"Taher A","year":"2009","unstructured":"Taher A, El-Beshlawy A, Elalfy MS, et al.. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009, 82:458-65. 10.1111\/j.1600-0609.2009.01228.x","journal-title":"Eur J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.049957","article-title":"Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with \u03b2-thalassemia major","volume":"97","author":"Pennell DJ","year":"2012","unstructured":"Pennell DJ, Porter JB, Cappellini MD, et al.. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with \u03b2-thalassemia major. Haematologica. 2012, 97:842-8. 10.3324\/haematol.2011.049957","journal-title":"Haematologica"},{"key":"ref11","article-title":"Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective","volume":"3","author":"Galanello R","year":"2007","unstructured":"Galanello R. Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag. 2007, 3:795-805.","journal-title":"Ther Clin Risk Manag"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2018.066","article-title":"Deferasirox: over a decade of experience in thalassemia","volume":"10","author":"Moukalled NM","year":"2018","unstructured":"Moukalled NM, Bou-Fakhredin R, Taher AT. Deferasirox: over a decade of experience in thalassemia. Mediterr J Hematol Infect Dis. 2018, 10:e2018066. 10.4084\/MJHID.2018.066","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-973845","article-title":"Recent developments in iron chelation therapy","volume":"219","author":"Cario H","year":"2007","unstructured":"Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E. Recent developments in iron chelation therapy. Klin Padiatr. 2007, 219:158-65. 10.1055\/s-2007-973845","journal-title":"Klin Padiatr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2012.10.006","article-title":"Combined chelation therapy with deferasirox and deferoxamine in thalassemia","volume":"50","author":"Lal A","year":"2013","unstructured":"Lal A, Porter J, Sweeters N, et al.. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis. 2013, 50:99-104. 10.1016\/j.bcmd.2012.10.006","journal-title":"Blood Cells Mol Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2014.04.006","article-title":"Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients","volume":"53","author":"Cassinerio E","year":"2014","unstructured":"Cassinerio E, Orofino N, Roghi A, et al.. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients. Blood Cells Mol Dis. 2014, 53:164-7. 10.1016\/j.bcmd.2014.04.006","journal-title":"Blood Cells Mol Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12507","article-title":"Efficacy and safety of a novel combination of two oral chelators deferasirox\/deferiprone over deferoxamine\/deferiprone in severely iron overloaded young beta thalassemia major patients","volume":"95","author":"Elalfy MS","year":"2015","unstructured":"Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Efficacy and safety of a novel combination of two oral chelators deferasirox\/deferiprone over deferoxamine\/deferiprone in severely iron overloaded young beta thalassemia major patients. Eur J Haematol. 2015, 95:411-20. 10.1111\/ejh.12507","journal-title":"Eur J Haematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25222","article-title":"Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients","volume":"93","author":"Pinto VM","year":"2018","unstructured":"Pinto VM, Balocco M, Quintino S, et al.. Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients. Am J Hematol. 2018, 93:E338-40. 10.1002\/ajh.25222","journal-title":"Am J Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08626.x","article-title":"Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies","volume":"154","author":"Voskaridou E","year":"2011","unstructured":"Voskaridou E, Christoulas D, Terpos E. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. Br J Haematol. 2011, 154:654-6. 10.1111\/j.1365-2141.2011.08626.x","journal-title":"Br J Haematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-0933-1","article-title":"Combining two orally active iron chelators for thalassemia","volume":"89","author":"Berdoukas V","year":"2010","unstructured":"Berdoukas V, Carson S, Nord A, et al.. Combining two orally active iron chelators for thalassemia. Ann Hematol. 2010, 89:1177-8. 10.1007\/s00277-010-0933-1","journal-title":"Ann Hematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4081\/cp.2017.912","article-title":"Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusion-dependent \u03b2-thalassemia major","volume":"7","author":"Karami H","year":"2017","unstructured":"Karami H, Kosaryan M, Amree AH, Darvishi-Khezri H, Mousavi M. Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusion-dependent \u03b2-thalassemia major. Clin Pract. 2017, 7:912. 10.4081\/cp.2017.912","journal-title":"Clin Pract"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref22","article-title":"RoB 2: A revised Cochrane risk-of-bias tool for randomized trials | Cochrane Bias [Internet]","author":"Cochrane Collaboration","year":"2022","unstructured":"Cochrane Collaboration. RoB 2: A revised Cochrane risk-of-bias tool for randomized trials | Cochrane Bias [Internet]. Br Med J. 2022, 1-24.","journal-title":"Br Med J"},{"key":"ref23","article-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses","author":"Wells G","year":"2021","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa Hospital Research Institute, Ottawa; 2021."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-016-0821-4","article-title":"Comparative efficacy and safety of oral iron chelators and their novel combination in children with thalassemia","volume":"53","author":"Gomber S","year":"2016","unstructured":"Gomber S, Jain P, Sharma S, Narang M. Comparative efficacy and safety of oral iron chelators and their novel combination in children with thalassemia. Indian Pediatr. 2016, 53:207-10. 10.1007\/s13312-016-0821-4","journal-title":"Indian Pediatr"},{"key":"ref25","article-title":"Advantages of deferiprone with deferasirox over deferiprone alone in iron chelation therapy of thalassaemic children","volume":"25","author":"Jahir S","year":"20192022","unstructured":"Jahir S, Anwar S, Morshed AA, Islam A, Islam K, Ahsan Khan MK. Advantages of deferiprone with deferasirox over deferiprone alone in iron chelation therapy of thalassaemic children. The Insight. 20192022, 25:3.","journal-title":"The Insight"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2011.03.007","article-title":"Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications","volume":"47","author":"Farmaki K","year":"2011","unstructured":"Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol Dis. 2011, 47:33-40. 10.1016\/j.bcmd.2011.03.007","journal-title":"Blood Cells Mol Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25533","article-title":"The deferiprone and deferasirox combination is efficacious in iron overloaded patients with \u03b2-thalassemia major: a prospective, single center, open-label study","volume":"62","author":"Totadri S","year":"2015","unstructured":"Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with \u03b2-thalassemia major: a prospective, single center, open-label study. Pediatr Blood Cancer. 2015, 62:1592-6. 10.1002\/pbc.25533","journal-title":"Pediatr Blood Cancer"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001269","article-title":"Advantages of deferiprone with deferasirox over deferiprone alone in iron chelation therapy of thalassaemic children","volume":"41","author":"Hammond J","year":"2019","unstructured":"Hammond J, Thompson AA, Fogel MA, Hammond K, Kokroko J, Kwiatkowski JL. Advantages of deferiprone with deferasirox over deferiprone alone in iron chelation therapy of thalassaemic children. J Pediatr Hematol Oncol. 2019, 41:e47-50. 10.1097\/MPH.0000000000001269","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11072010","article-title":"Safety and efficacy of the new combination iron chelation regimens in patients with transfusion-dependent thalassemia and severe iron overload","volume":"11","author":"Origa R","year":"2022","unstructured":"Origa R, Cinus M, Pilia MP, et al.. Safety and efficacy of the new combination iron chelation regimens in patients with transfusion-dependent thalassemia and severe iron overload. J Clin Med. 2022, 11:11. 10.3390\/jcm11072010","journal-title":"J Clin Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/1532-429X-11-20","article-title":"The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study","volume":"11","author":"Berdoukas V","year":"2009","unstructured":"Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson. 2009, 11:20. 10.1186\/1532-429X-11-20","journal-title":"J Cardiovasc Magn Reson"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1989.tb01411.x","article-title":"Twenty-four hour variation of transferrin saturation in treated and untreated haemochromatosis homozygotes","volume":"226","author":"Edwards CQ","year":"1989","unstructured":"Edwards CQ, Griffen LM, Kaplan J, Kushner JP. Twenty-four hour variation of transferrin saturation in treated and untreated haemochromatosis homozygotes. J Intern Med. 1989, 226:373-9. 10.1111\/j.1365-2796.1989.tb01411.x","journal-title":"J Intern Med"},{"key":"ref32","article-title":"Current strategies in the assessment of iron overload","volume":"28","author":"Taher AT","year":"2022","unstructured":"Taher AT, Musallam KM, Hoffbrand AV. Current strategies in the assessment of iron overload. Eur J Clin Med Oncol. 2022, 28:","journal-title":"Eur J Clin Med Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0177","article-title":"Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance","volume":"105","author":"St Pierre TG","year":"2005","unstructured":"St Pierre TG, Clark PR, Chua-anusorn W, et al.. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005, 105:855-61. 10.1182\/blood-2004-01-0177","journal-title":"Blood"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2021.0290","article-title":"The evaluation of iron deficiency and iron overload","volume":"118","author":"Gattermann N","year":"2021","unstructured":"Gattermann N, Muckenthaler MU, Kulozik AE, Metzgeroth G, Hastka J. The evaluation of iron deficiency and iron overload. Dtsch Arztebl Int. 2021, 118:847-56. 10.3238\/arztebl.m2021.0290","journal-title":"Dtsch Arztebl Int"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.10.001","article-title":"Iron chelation in thalassemia major","volume":"37","author":"Borgna-Pignatti C","year":"2015","unstructured":"Borgna-Pignatti C, Marsella M. Iron chelation in thalassemia major. Clin Ther. 2015, 37:2866-77. 10.1016\/j.clinthera.2015.10.001","journal-title":"Clin Ther"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6207","article-title":"The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration","volume":"52","author":"Hadziahmetovic M","year":"2011","unstructured":"Hadziahmetovic M, Song Y, Wolkow N, et al.. The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration. Invest Ophthalmol Vis Sci. 2011, 52:959-68. 10.1167\/iovs.10-6207","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S61540","article-title":"Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives","volume":"7","author":"Bayanzay K","year":"2016","unstructured":"Bayanzay K, Alzoebie L. Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives. J Blood Med. 2016, 7:159-69. 10.2147\/JBM.S61540","journal-title":"J Blood Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004839.pub2","article-title":"Oral deferiprone for iron chelation in people with thalassaemia","author":"Roberts DJ","year":"2007","unstructured":"Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev. 2007, CD004839. 10.1002\/14651858.CD004839.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/297641","article-title":"Health-related quality of life, treatment satisfaction, adherence and persistence in \u03b2-thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: results from the epic clinical trial","volume":"2012","author":"Porter J","year":"2012","unstructured":"Porter J, Bowden DK, Economou M, et al.. Health-related quality of life, treatment satisfaction, adherence and persistence in \u03b2-thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: results from the epic clinical trial. Anemia. 2012, 2012:297641. 10.1155\/2012\/297641","journal-title":"Anemia"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/172061-efficacy-and-safety-of-combined-deferiprone-and-deferasirox-in-iron-overloaded-patients-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:05Z","timestamp":1707509405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/172061-efficacy-and-safety-of-combined-deferiprone-and-deferasirox-in-iron-overloaded-patients-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,4]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.48276","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,4]]}}}